The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors.
Opioids, acting via G-protein coupled membrane receptors, induce analgesia. However their role is not limited to their anti-nociceptive action. They are found in several peripheral tissues acting as negative regulators of cellular processes. Even though that is not fully elucidated, it becomes obvious that opioids exert their effects in close relation to other neuropeptides such as somatostatin. Hepatocellular carcinoma is one tumor, among others, which secrete bioactive peptides while somatostatin analogs exert an inhibitory effect. We have used the human hepatocyte-derived cancer cell line HepG2, in order to examine the effect of opioids on cell growth and their possible mode of action. Our results show that the opioid ethylketocyclazocine (EKC) inhibits cell proliferation and induces apoptosis. This inhibitory effect is not exerted via opioids receptors since it was not reversed by the opioid antagonist diprenorphine and functional opioid receptors were not found on HepG2 cells. On the contrary, we show that EKC binds to somatostatin receptors, and activates a PTP signalling cascade. In this respect, the interaction of opioids with somatostatin receptors on hepatocellular carcinoma cells, and the fact that they are widely used for pain control, may provide some additional clues for the discrepancies during treatment with somatostatin analogues.
Notas
George
G
Laboratory of Gastroenterology and Hepatology, School of Medicine, University of Crete, Heraklion, Crete, Greece.
Kampa
Marilena
M
Nifli
Artemissia-Phoebe
AP
Xidakis
Kostas
K
Papasava
Despoina
D
Thermos
Kyriaki
K
Kouroumalis
Elias
E
Castanas
Elias
E
D000701:Analgesics, Opioid / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004174:Diprenorphine / Q000494:pharmacology; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D016308:Enkephalin, Leucine-2-Alanine / Q000494:pharmacology; D016314:Ethylketocyclazocine / Q000494:pharmacology*; D006801:Humans; D009292:Narcotic Antagonists / Q000494:pharmacology; D015282:Octreotide / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D011957:Receptors, Opioid / Q000235:genetics / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000378:metabolism*; D013004:Somatostatin / Q000378:metabolism
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D012333:RNA, Messenger; D011957:Receptors, Opioid; D017481:Receptors, Somatostatin; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004174:Diprenorphine; D013004:Somatostatin; D016314:Ethylketocyclazocine; D016308:Enkephalin, Leucine-2-Alanine; D015282:Octreotide